GSK Shares - Search News

Hosted on MSN · 1h

GSK launches $2.5 billion buyback, lifts sales target after stellar Q4

GSK launched a 2 billion pounds ($2.5 billion) share buyback on Wednesday and lifted its long-term sales target to nearly $50 billion, betting that growing sales of its HIV and cancer drugs will make up for pressures on its vaccines revenue.

The Financial Times · 5h

GSK launches £2bn buyback on strong HIV and cancer drugs sales

GSK launched a rare £2bn share buyback and raised its growth targets on the back of strong sales of speciality medicines including cancer and HIV drugs, sending shares up as much as 6 per cent on Wednesday.

The Wall Street Journal on MSN · 3h

GSK Launches $2.5 Billion Buyback, Raises Midterm Sales Outlook

The pharmaceutical company said promising pipeline developments and high demand for drugs in its specialty segment lifted fourth-quarter profit ahead of analyst expectations.

Bloomberg on MSN · 6h

GSK Plans £2 Billion Share Buyback, Boosts Long-Term Outlook

GSK Plc plans to buy back £2 billion ($2.5 billion) of shares as it raised its long-term growth outlook on optimism around the drug pipeline.

Seeking Alpha on MSN · 1h

GSK raises long-term guidance, announces buybacks

GSK shares added ~6% in London trading on Wednesday after the British drugmaker lifted its 2031 outlook and announced a new share buyback program alongside better-than-expected earnings for Q4 2025. The company disclosed £8.

34m

GSK Stock Up On Q4 Results, Positive Outlook; Plans To Buyback GBP 2 Bln Shares

Shares of GSK Plc. were gaining around 6 percent on the London Stock Exchange, as well as in the pre-market activity on the NYSE, ...

5hon MSN

GSK shares surge around 6% as drugmaker raises sales target and boosts dividends

Shares of British pharmaceutical giant GSK surged on Wednesday after the company raised its long-term sales forecast and ...

7hon MSN

GSK Announces £2 Billion Share Buyback as Profit Beats Estimates

GSK Plc announced a share buyback of £2 billion as it saw better than expected profit in the fourth quarter. The share ...

2h

GSK Q4 Earnings: Revenue And EPS Beat, Initiates $2.5 Billion Stock Buyback, Raises Long-Term Annual Sales Forecast To Over $50 Billion

GSK's Q4 sales hit $10.40 billion, topping estimates. Specialty Medicines grew 14%, while vaccines declined. The company ...

4hon MSN

Miners drive robust FTSE 100, Future shares higher on US progress

GSK’s 6% results-day share price advance is the standout performance in an otherwise subdued FTSE 100 index. Miner Fresnillo ...

3h

GSK intends to commence GBP 2B share buyback program

Q4 2024 dividend of 16p declared; 61p FY 2024; 64p expected for 2025. GSK (GSK) now intends to commence a GBP 2B share buyback programme, to be ...

8h

GSK beats Q4 earnings estimates, lifts 2031 sales target

GSK forecast sales in 2025 to grow 3%-5% and reported better-than-expected fourth-quarter earnings, as strength in its HIV ...

5hon MSN

GSK targets £40bn in sales as HIV and cancer drugs offset vaccine weakness

The pharmaceutical giant is now targeting more than £40billion in annual revenue by 2031, compared to a previous outlook of £38billion.

GSK Raises 2031 Sales Forecast to £40B Amid Strong Specialty Medicine Growth

GSK (LON:GSK) has raised its long-term revenue outlook, now expecting sales to exceed 40 billion by 2031, up from 38 billion.

2h

GSK lifts long-term sales targets on new drug pipeline

Pharmaceuticals giant GlaxoSmithKline ( GSK.L) (GSK) has lifted its long-term sales guidance as it hailed a strong drugs ...

21h

GSK falls Tuesday, underperforms market

GSK PLC closed 24.32% short of its 52-week high of £18.24, which the company achieved on May 16th.

Results that may be inaccessible to you are currently showing.

Hide inaccessible results